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Abstract: Clearance of red blood cells and hemoproteins is a key metabolic function of macrophages dur-
ing hemolytic disorders and following tissue injury. Through this archetypical phagocytic function, heme
is detoxified and iron is recycled to support erythropoiesis. Reciprocal interaction of heme metabolism
and inflammatory macrophage functions may modify disease outcomes in a broad range of clinical con-
ditions. We hypothesized that acute hemolysis and heme induce acute anti-inflammatory signals in liver
macrophages. Using a macrophage-driven model of sterile liver inflammation, we showed that phenyl-
hydrazine (PHZ)-mediated acute erythrophagocytosis blocked the anti-CD40 antibody-induced pathway
of macrophage activation. This process attenuated the inflammatory cytokine release syndrome and
necrotizing hepatitis induced by anti-CD40 antibody treatment of mice. We further established that
administration of heme-albumin complexes specifically delivered heme to liver macrophages and repli-
cated the anti-inflammatory effect of hemolysis. The anti-inflammatory heme-signal was induced in
macrophages by an increased intracellular concentration of the porphyrin independently of iron. Over-
all, our work suggests that induction of heme-signaling strongly suppresses inflammatory macrophage
function, providing protection against sterile liver inflammation.
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Clearance of red blood cells and hemoproteins is a key metabolic function of
macrophages during hemolytic disorders and following tissue injury. Through this
archetypical phagocytic function, heme is detoxified and iron is recycled to support
erythropoiesis. Reciprocal interaction of heme metabolism and inflammatory macrophage
functions may modify disease outcomes in a broad range of clinical conditions. We
hypothesized that acute hemolysis and heme induce acute anti-inflammatory signals in
liver macrophages. Using a macrophage-driven model of sterile liver inflammation, we
showed that phenylhydrazine (PHZ)-mediated acute erythrophagocytosis blocked the
anti-CD40 antibody-induced pathway of macrophage activation. This process attenuated
the inflammatory cytokine release syndrome and necrotizing hepatitis induced by anti-
CD40 antibody treatment of mice. We further established that administration of heme-
albumin complexes specifically delivered heme to liver macrophages and replicated the
anti-inflammatory effect of hemolysis. The anti-inflammatory heme-signal was induced in
macrophages by an increased intracellular concentration of the porphyrin independently
of iron. Overall, our work suggests that induction of heme-signaling strongly suppresses
inflammatory macrophage function, providing protection against sterile liver inflammation.
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INTRODUCTION
During hemolysis and in conditions with a localized breakdown of red blood cells (RBCs),
erythrophagocytosis and heme-clearance are critical metabolic functions of macrophages (1).
This is particularly true for liver macrophages, which are the primary phagocytes that eliminate
damaged RBCs during systemic hemolysis (2). Through this archetypical function, macrophages
prevent the release of toxic cell-free hemoglobin and heme into the bloodstream or tissues, and iron
is recycled to supply erythropoiesis (1–7).
Heme is a disease modifier that may act as a damage-associated molecular pattern (DAMP) and
amplify inflammatory responses (8, 9). Once released from cells or hemoproteins, cell-free heme can
activate Toll-like receptors (such as TLR4) on the cell surface of leukocytes and endothelial cells,
leading to inflammatory signal activation (10, 11). This mechanism can cause endothelial cell
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activation and vaso-occlusion during a hemolytic crisis with
enhanced extracellular heme exposure in sickle cell disease (11–
13). The spectrum of hemoglobin and heme triggered adverse
physiological effects enforced the evolution of highly effective
systems to minimize extracellular hemoglobin and heme
exposures (1, 14–17). In most conditions, macrophages
internalize damaged but still intact RBCs by erythrophagocytosis
before they disintegrate within the circulation (2). Even if
intravascular hemolysis occurs, an efficient system of scavenger
proteins, including haptoglobin, hemopexin, alpha1-
microglobulin, and albumin capture cell-free hemoglobin and
heme for subsequent clearance by macrophages and, potentially,
other cell types (14, 18–20).
Growing evidence indicates that heme accumulation in
macrophages that results from erythrophagocytosis or heme
clearance is a suppressor of inflammation and innate immunity
(21–25). In chronic genetic hemolytic anemia, erythrophagocytosis
profoundly modified the landscape of liver macrophages, skewing
their transformation into anti-inflammatory erythrophagocytes
that attenuated immune-mediated acute and chronic pathologies
in the liver (22). Intracellular heme signaling may also compromise
host defense to bacterial infections and adversely affect survival in
sepsis (23, 26).
This study investigated how macrophage RBC metabolism
and heme may acutely suppress innate immune activation
transmitted by non-infectious signaling through CD40
signaling, which induces a macrophage-driven necro-
inflammatory liver disease in mice.
METHODS
Animal Models and Experiments
Wild-type C57BL/6J mice were obtained from Charles River
(Wilmington, MA, USA). Tamoxifen-inducible Hmox1
knockout mice: Hmox1tm1.1Hes were obtained from Harald
Esterbauer and crossed with B6.Cg(UBC‐cre/ERT2)1Ejb/J. All
mice were housed and bred under specific-pathogen-free
conditions at the Laboratory Animal Services Center (LASC)
of the University of Zürich. Eight to ten week-old males and
females were used in all experiments.
Study Approval
All experimental protocols were reviewed and approved by the
Veterinary Office of the Canton of Zürich. All animals were
treated in accordance with the guidelines of the Swiss Federal
Veterinary Office.
Phenylhydrazine (PHZ) Induced Systemic Hemolysis
C57BL/6J mice were treated intraperitoneally (i.p.) with 90 mg/
kg PHZ hydrochloride. After 12 or 30 h of PHZ injection, blood
was removed by heart puncture; livers were collected, digested,
and macrophages were purified by magnetic-activated cell
sorting (MACS) or anti-F4/80 antibody coated Dynabeads. The
concentration of heme was quantified in F4/80+ macrophages
using the oxalic acid method described by Sassa et al. (27) using
oxalic acid purchased from Sigma-Aldrich (#194131).
In Vivo Injections of Porphyrins
C57BL/6J mice were treated intraperitoneally (i.p.) with 70 µmol/
kg of heme-albumin, SnMP, or ZnPP.
Agonistic Anti-CD40-Antibody-Induced Systemic
Inflammation and Hepatitis In Vivo Model
Mice were treated intraperitoneally (i.p.) with 20 mg/kg agonistic
anti-CD40 antibody (InVivoPlus, clone FGK4.5/FGK45). After
12 or 30 h of anti-CD40 antibody injection, blood samples were
removed by terminal heart puncture for determination of AST/
ALT levels (Reflotron AST 10745120, ALT 10745138, Roche) or
cytokine measurement (Bio-rad, Bioplex), and the livers excised
48 h after anti-CD40 antibody injection.
PHZ Preparation
PHZ hydrochloride (Sigma Aldrich, 114715-100g) solutions
were prepared by adding 112.5 mg of PHZ to 5 mL PBS. The
pH of the solutions was then brought to 7.4, using NaOH 1 M,
and 5 mL of PBS was added to a total volume of 10 mL. The
solutions were sterile-filtered (0.22 µm) and used immediately.
Porphyrin Preparation
Hemin (heme-chloride) was obtained from Sigma (#51280),
SnMP (tin mesoporphyrin, FSISnM321), MnPP (manganese
protoporphyrin, FSISnM321), and ZnPP (zinc protoporphyrin,
FSIZn625-9) were all obtained from Frontiers. All porphyrins
were dissolved in 10 mL NaOH (100 mM) at 37°C, and then 10
mL of 20% human serum albumin (CSL Behring AG) was added.
After 1 h of incubation at 37°C, the pH of the solution was
adjusted to pH 7.8, using ortho-phosphoric acid, and the final
volume was adjusted to 25 mL with deionized water. The
porphyrin-albumin solutions were sterile-filtered (0.22 µm)
and used immediately (28).
Bone Marrow Derived-Macrophage
Culture and Stimulation
Bone marrow (BM) cells were obtained from femurs and tibias of
8–10-week-old mice and differentiated in RPMI medium
supplemented with 10% FCS and recombinant mouse M-CSF
(PeproTech 315-02, lot 0914245) at 100 ng/mL for up to 7 days.
At the end of the culture period, the cells were differentiated in
BMDMs; 100% of adherent cells were positive for F4/80 antigen
as measured by flow cytometry. Hmox1 tissue-specific deficient
BMDMs were treated with 4-hydroxytamoxifen (Sigma H7904)
24 h before starting the experiments.
Isolation of Liver Macrophages
Mice were anesthetized by intraperitoneal injection of ketamine
(80 mg/kg), xylazine (16 mg/kg), and acepromazine (3 mg/kg).
Laparotomy was performed to access the portal vein, which was
then catheterized for in situ liver digestion with 0.4 mg/ml
collagenase B buffered solution (Roche, 11088815001). After
digestion, the mice were sacrificed, and their livers were
excised, mechanically disaggregated in a petri dish on ice, and
filtered through a 100 mm pore cell strainer. The cell suspension
was subjected to two rounds of centrifugation (60 ×g, 2 min at
4°C), and the pellet was discarded. The supernatants were then
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centrifuged once more (300 ×g, 5 min at 4°C) to obtain a pellet of
nonparenchymal cells containing liver macrophages [protocol
modified from (29)].
Macrophage Enrichment With Magnetic
Beads
Dynabeads-Based Cell Enrichment
To positively select F4/80+ macrophages from liver cell
suspensions for mRNA extraction, Dynabeads Sheep anti-Rat
IgG (Invitrogen, 11035), in combination with purified Rat anti-
mouse F4/80 antibody (BD Pharmigen, 0.5 mg/ml, 565409) and
DynaMag™-2 Magnet (Thermo Fisher Scientific, 12321D) were
used according to the manufacturer’s protocol for positive
selection (Invitrogen). The purity of the separated cells was
more than 95% for the F4/80 antigen.
Microbeads-Based Cell Enrichement
To positively select F4/80+ macrophages from liver cell
suspensions, anti-F4/80 MicroBeads UltraPure (Miltenyi, cat.
n. 130-110-443), and magnetic cell separation LS columns
(Miltenyi, cat. n. 130-042-401), and the QuadroMACS
Separator (Miltenyi, cat. n. 130-090-976) were used for MACS
according to the manufacturer’s protocol (Miltenyi). The purity
of the separated cells was more than 95% for the F4/80 antigen.
Flow Cytometry
Macrophages were pre-incubated with LIVE/DEAD Fixable Near-
IR cell stain kit (Invitrogen, L34976) and withMouse BD Fc Block™
(≤ 1 mg/million cells in 100 mL, BD Biosciences #553141) at 4°C for
5 min and then stained with Pacific Blue anti-CD45 (5 µg/mL,
BioLegend #109820), anti-CD11b FITC (5 µg/mL, BD Biosciences
#557396), anti-CD11b APC-cy7 (2 µg/mL, BioLegend #101226),
anti-F4/80 APC (5 µg/mL, BioLegend 123116), or anti-F4/80 PE (2
µg/mL, BD Pharmigen 565410) antibodies. After cells were fixed
with formaldehyde 2% and permeabilized with permeabilization
buffer (eBioscience, #00-8333-56), ingested erythrocytes were
stained intracellularly with anti-TER-119 PE (2 µg/mL, Stemcell
#60033) antibody. Stained cells were analyzed using the LSRFortessa
(BD) or the SP6800 Spectral Analyzer (Sony). Data were analyzed
using FlowJo and FCS express 6 (De Novo software).
Gene Expression Analysis
Microarray Experiments and Data Analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol,
including on-column DNA digestion (RNase-Free DNase Set;
Qiagen Hombrechtikon, Switzerland). The quality of each RNA
sample was measured on an RNA Nanochip with a Bioanalyzer
2100 (Agilent Technologies), and only high-quality RNA (RNA
integrity number > 7.0) was used for gene expression analysis.
RNA quantification was performed spectrophotometrically using
a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Fluorescently labeled
cRNA was produced from 500 ng of total RNA using the Quick
Amp Labeling Kit (Agilent Technologies) according to the
manufacturer’s protocol. Differential gene expression profiling was
performed by competitive dual-color hybridization on whole mouse
genome oligo microarrays (mouse: G4846A, Agilent Technologies).
Array slides were XDR-scanned and analyzed using the Feature
Extraction Software Version 10.7.3.1 (Agilent Technologies).
Statistical analysis and visualization were performed using JMP
Genomics 7.0 (SAS Institute, Boeblingen, Germany). Full gene array
data were submitted to the Gene Expression Omnibus.
Real-Time Quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen
Hombrechtikon, Switzerland) and reverse transcription was
performed with TaqMan reverse transcription reagents (Life
Technologies, Basel , Switzerland), according to the
manufacturer’s protocol.
Real-time qPCR (RT-qPCR) was performed using the Fast
SYBR™ Green Master Mix (Applied Biosystems, 4385612) to
determine the expression levels of the target genes listed in Table
1 below. Relative mRNA levels were calculated using the 7500
Fast System Sequence Detection Software Version 1.4 (Applied
Biosystems) and normalized to Hprt levels for each
experimental sample.
Western Blotting
Westernblottingwasperformedusing10mg samples of total protein
per well suspended in Lämmli buffer as previously described (30).
The western blot protocol included fluorescence detection of the
secondary HRP-labeled antibodies (Amersham, GE Healthcare,
Glattbrugg, Switzerland) with the SuperSignal West Femto
Maximum Sensitivity Substrate Kit (Thermo Scientific #AG
34095). Images were optimized by adjusting the brightness and
contrast of the entire image using Photoshop software (Adobe,
Adobe Systems GmbH, Zürich, Switzerland). The primary
antibodies were pAb anti-HMOX1 antibody (Enzo Life Sciences
#ADI-SPA-895) used at a final concentration of 0.2 µg/L.
Bio-Plex Cytokine Assay
Concentrations of IL6, TNFa, IL12p40, CCL2, CCL4, and CCL5
were determined using the Bio-Plex Cytokine Assays (Bio-Rad).
The assay was performed using a Bio-Plex 200 system (Bio-Rad).
TABLE 1 | Primer pairs for the genes analyzed in gene expression analysis.
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The results were analyzed using the Bio-Plex Data Pro software
(Bio-Rad).
Metabolic Flux Analysis
Mitochondrial function (oxygen consumption rate) and
glycolysis (acidification rate) of BMDMs were measured with a
Seahorse XF24 extracellular flux analyzer using the Cell Mito
Stress Kit (Agilent Technologies) according to the
manufacturer’s instructions.
Histology
An Olympus IX71 microscope was used for macroscopic
imaging of fresh liver and spleen tissue samples. For
histological images, the liver and spleen were fixed in 10%
formalin for 48 h at room temperature and embedded in
paraffin. Microtome sections (5 mm thick) were stained with
hematoxylin and eosin (H&E) and photographed using a Zeiss
Apotome.2 microscope.
Statistical Analysis
Data plotting and statistical analyses were performed using
GraphPad (Prism 7, San Diego). For comparison of multiple
groups, we used analysis of variance (ANOVA) with Tukey’s post
hoc test. Two-way hierarchical clustering analyses were
performed using the Ward algorithm, as provided by JMP14
software (SAS, Germany).
RESULTS
Phenylhydrazine Treatment Induces Acute
Heinz Body Anemia With Acute
Erythrophagocytosis in C57BL/6J Mice
Twenty-four hours after a single injection of phenylhydrazine
(PHZ), we detected fluorescent Heinz bodies in the circulating
RBCs (Figure 1A). This was accompanied by extensive
erythrophagocytosis of TER119+ RBCs by F4/80+ macrophages
in the liver (Figure 1B), followed by a decrease in the hematocrit
(Figure 1C). Accordingly, F4/80+ macrophages isolated from the
livers of PHZ-treated animals 48 h after the PHZ injection
presented increased intracellular concentrations of heme





FIGURE 1 | PHZ administration induces acute erythrophagocytosis in F4/80+ liver macrophages C57Bl/6J mice were treated with saline (control) or phenylhydrazine
(PHZ, 90 mg/kg) and sacrificed 24 or 48 h later for blood and organ collection. (A) RBCs of saline- and PHZ-treated C57Bl/6J mice. Upper panels: DIC brightfield
image at 600x magnification, lower panels: autofluorescence of Heinz bodies in the green fluorescence channel. (B) Representative flow cytometry density plots of
liver cells stained for F4/80 and intracellular TER-119 and gated from CD45+ liver cells. Data were obtained from a control mouse and a mouse after PHZ treatment.
(C) Hematocrit of saline- and PHZ-treated mice at 48 h (n = 7–10). (D) Heme concentrations in purified F4/80+ liver macrophages isolated by positive selection using
anti-F4/80 antibody coated magnetic beads, followed by magnetic-activated cell sorting (MACS) from control and PHZ-treated mice (n=5). Heme concentration was
normalized to total protein levels in each group. No significant difference in total protein levels was observed between groups. (E) Representative photographs of cell
pellets of purified F4/80+ liver macrophages from saline- and PHZ-treated mice. Individual symbols represent one mouse; ****p < 0.0001 and ***p < 0.001.
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PHZ Attenuates the Anti-CD40 Antibody-
Driven Disease Phenotype by Suppressing
Liver Macrophage Inflammation
We injected mice with an agonistic anti-CD40 antibody as a
model of macrophage-driven inflammatory disease. This
treatment induced an acute systemic inflammatory response
syndrome with necrotizing hepatitis (31, 32), which was mainly
driven by macrophage activation (33). We found that
administration of PHZ 48 h before antibody injection
suppressed the anti-CD40 antibody-induced disease
phenotype, preventing the occurrence of macroscopic and
microscopic liver infarcts, and the release of alanine
transaminase (ALT) and pro-inflammatory cytokines into the
plasma (Figures 2A–C). To specifically determine whether PHZ
blunts the inflammatory response at the level of liver
macrophages, F4/80 positive cells were isolated with
Dynabeads following in situ liver digestion for 16 h after anti-
CD40 antibody administration. Figure 2D shows a hierarchical
clustering analysis of pro-inflammatory cytokines and Hmox1
mRNA expression in liver F4/80 positive macrophages of PHZ-
treated and untreated animals. A clear segregation was observed
in the PHZ-treated and untreated animals in response to anti-
CD40, suggesting that PHZ blocked the disease phenotype by
repressing macrophage inflammation. No inflammatory





FIGURE 2 | PHZ administration prevents anti-CD40 antibody induced inflammatory liver disease. C57Bl/6J mice were treated with saline (control) or PHZ (90 mg/
kg) at T0h, 48 h later with anti-CD40 antibody (20 mg/kg) (T48h). The animals were sacrificed at T60h for plasma cytokines, at T78h for liver enzymes, and at T96h for
liver histology. (A) Representative photographs of liver lobes and H&E-stained liver tissue sections. Ischemic infarcts were detected in the anti-CD40 antibody-treated
mice (visible as white spots on the liver lobes in the area within the violet dashed line on histology). (B) Plasma concentrations of ALT in C57BL/6J mice after
treatment with PHZ and/or anti-CD40 antibody (n = 5). (C) Heatmap displaying color-coded plasma concentrations of IL6, IL12p40, TNFa, CCL2, and CCL5 in
C57BL/6J mice after treatment with PHZ or anti-CD40 antibody (n = 4) (yellow=low expression, red=high expression). (D) Heatmap displaying color-coded mRNA
expression levels of pro-inflammatory cytokines and Hmox1 from Dynabeads-enriched F4/80 positive liver macrophages in C57BL/6J mice after treatment with PHZ
or an anti-CD40 antibody (n = 3) (yellow=low expression, red=high expression). mRNA expression was measured by qRT-PCR. Individual symbols represent one
mouse; ****p < 0.0001.
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Porphyrin-Albumin Complexes Deliver
Heme Into Liver Macrophages
PHZ administration resulted in extensive erythrophagocytosis by
liver macrophages and, consequently, high levels of intracellular
heme as a result of RBC metabolism. This led us to believe that
heme could be the key driver of macrophage suppression,
resulting in protection from anti-CD40-induced inflammatory
liver disease. To further explore the role of heme in hemolysis-
induced macrophage suppression, we established a model to
specifically deliver heme into liver macrophages in vivo. We have
previously described that heme-albumin complexes are useful in
vitro to induce heme-specific responses in macrophages, while
the proinflammatory adverse effects of free heme could be
avoided (21, 22). Zinc protoporphyrin (ZnPP) has a
fluorescence emission spectrum with two peaks at 591 nm and
647 nm when excited at 405 nm (Figure 3A). Using a spectral
flow cytometer, we detected the same specific ZnPP emission
spectrum in F4/80+ macrophages isolated from the liver of mice
2 h after intraperitoneal injection of ZnPP-albumin (Figure 3B).
In contrast, no ZnPP-signal was recorded in the F4/80 negative
leukocyte population, indicating that porphyrin-albumin
complexes were preferentially delivered to liver macrophages.
To determine the effects of heme-albumin administration
on liver macrophage homeostasis, we characterized liver
macrophages by flow cytometry before and 4, 16, and 24 h
after heme-albumin injection (Figure 3C). Heme-albumin
administration induced a time-dependent recruitment of
CD45+/CD11b+ monocytes into the liver. The F4/80+ Kupffer
cell population remained unaltered, suggesting that the anti-
inflammatory effects of heme-albumin described below cannot
be explained by macrophage depletion. Collectively, these results
suggested that heme-albumin complexes could be used as a





FIGURE 3 | Selective uptake of ZnPP-albumin by F4/80+ liver macrophages (A) Excitation (dotted black line) and emission (full red line) spectra of ZnPP-albumin
excited at 405 nm measured in solution. (B) Spectral plots recorded with a spectral cell analyzer for the CD45+/F4/80+ (red) and CD45+/F4/80- (blue) leukocyte
populations in a suspension of liver cells from a C57BL/6J mouse treated with ZnPP-albumin. Livers were collected 2 h after the injection. The plots show the cell
density on an intensity-wavelength matrix. The red line (area of highest density) indicates the excitation spectrum of the selected cell population. (C) Representative
flow cytometry density plots of liver single cell suspensions stained for CD11b and F4/80 and gated for live CD45+ cells. Livers were collected before (0 h) and 4, 16,
or 24 h after heme-albumin injection.
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Heme-Albumin Treatment Attenuates the
Anti-CD40 Antibody-Driven Disease
Phenotype by Suppressing Liver
Macrophage Inflammation
To evaluate whether heme could reproduce the anti-
inflammatory effects of PHZ, C57BL/6J mice were treated with
heme-albumin and, 4 h later, with anti-CD40 antibody. We
found that maximum induction of Hmox1 and Nrf2 target genes
as surrogate markers of intracellular heme-exposure was reached
in liver macrophages four hours after a single injection of 70
µmol/kg heme-albumin (data not shown).
In contrast to saline-treated animals, heme-treated animals
displayed no visible liver necrosis (Figure 4A). Additionally,
based on plasma concentrations of TNFa, IL6, and liver
enzymes, the hierarchical clustering analysis in Figure 4C
shows the clear segregation of heme-and saline-treated animals
that were all injected with anti-CD40 antibodies. In contrast, no
apparent segregation was visible among the control, heme-
treated, and heme+anti-CD40 treated animals. Figure 4D
shows a clustering analysis of the mRNA expression of
proinflammatory genes in liver macrophages isolated with F4/
80 antibody coated magnetic Dynabeads 16 h after anti-CD40
injection. Again, a clear dichotomous expression profile was
observed in heme-treated and saline-treated animals in
response to the anti-CD40 antibody. This indicates that heme




FIGURE 4 | Heme-albumin administration prevents anti-CD40 antibody driven inflammatory liver disease. C57Bl/6J mice were injected with heme-albumin (70 µmol/
kg, i.p.) and after 4 h with anti-CD40 antibody (20 mg/kg). The animals were sacrificed at T16h for plasma cytokines or mRNA gene expression, at T34h for liver
enzymes, and at T52h for liver histology. (A) Representative macroscopic photographs of the liver lobe from mice injected with anti-CD40 antibody, with or without
heme-albumin. Necrosis is visible as a white spot. (B) Representative macroscopic images of the spleen of mice treated with anti-CD40 antibody, with or without
heme-albumin. Displayed is the average size of the spleens (mm) ± 2 SDs. (C) Heatmap displaying the color-coded plasma concentrations of IL6, TNFa, and liver
enzymes (ALT and AST) in animals treated with heme-albumin (heme) or albumin (control) and challenged with or without anti-CD40 antibody (yellow=low
concentration, red=high concentration). (D) Heatmap displaying the color-coded mRNA expression levels of proinflammatory cytokines in Dynabeads-enriched
F4/80+ liver macrophages in C57BL/6J mice that were treated with heme-albumin (heme) or albumin (control) and stimulated with or without anti-CD40 antibody.
These data demonstrate that acute heme-albumin treatment mitigated macrophage-driven inflammation and suppressed anti-CD40 antibody mediated disease.
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preventing the disease process induced by anti-CD40 in the liver.
The enlargement of the spleen, which is a result of CD40-
mediated B-cell activation and proliferation (34, 35) was
however not affected by heme treatment (Figure 4B).
Macrophage Suppression Is Independent
of Heme Iron
To investigate the role of iron in the anti-inflammatory effects
of heme on macrophage-driven anti-CD40 disease, we
conducted experiments using the iron-substituted heme-
analogs manganese protoporphyrin (MnPP) and tin
mesoporphyrin (SnMP). Bone marrow derived-macrophages
(BMDMs) incubated with either MnPP or SnMP for 4 h before
LPS stimulation showed markedly reduced pro-inflammatory
cytokine expression with mild Hmox1 expression (Figure 5A).
To confirm this finding in mice, we repeated the sequential
heme-albumin plus anti-CD40 antibody experiments
substituting SnMP for heme-albumin. SnMP is known to
have a favorable toxicity profile because it has been extensively
studied as a potential treatment for neonatal hyperbilirubinemia
(36, 37). SnMP-albumin-treated mice were challenged with
anti-CD40 antibody for 4 h. Mice treated with SnMP, but not
those treated with saline, were protected from anti-CD40
induced hepatitis, as reflected by the significantly lower plasma
transaminase levels (Figure 5B).
Intracellular Heme and Not Its Metabolites
Suppress Macrophage Inflammation
Heme levels in macrophages are defined by the flux of
extracellular heme into the cell (e.g., via erythrophagocytosis or
heme-uptake) and by intracellular heme catabolism through
heme oxygenases, primarily HMOX1. The observation that the
potent heme oxygenase inhibitors SnMP and MnPP (36) had
effects on macrophage inflammation that were comparable to
those of heme suggested that the anti-inflammatory effects were
directly transmitted by the porphyrins and not by metabolites
derived from heme breakdown by heme oxygenases. To confirm
this hypothesis, we generated an in vitromacrophage model with
tamoxifen-inducible Hmox1 deletion. Tamoxifen-treated
Hmox1fl/fl UBC Cre-ERT2 macrophages did not produce
HMOX1 in response to heme (Figure 6A), nor did they show
the classical increase in metabolic activity observed in wild-type
macrophages metabolizing heme (Figure 6B) (38). In the first set
of experiments, we compared the response of wild-type and
Hmox1-deficient mouse BMDMs to LPS-treated mice in the
absence of extracellular heme. Figure 6C shows the correlation
plot of the changes in gene expression induced by LPS treatment
for all genes represented on the gene array in the Hmox1 wild-
type (x-axis) and knockout macrophages model (y-axis). These
findings demonstrate that the LPS response in the absence of
heme is comparable in the two cell types (details of all gene array
experiments can be found in the Supplementary Excel File).
In subsequent experiments, we analyzed the effects of 50 µM
and 200 µM heme-albumin on LPS-induced gene expression.
Figure 6D shows the effects of heme-albumin on LPS-regulated
expression of two defined gene subsets. The ‘LPS-response’ gene
set contained all genes that were upregulated in BMDMs by LPS
in our experiments. The ‘inflammatory response’ gene set
displayed in the right panel is a predefined gene set from the
Hallmark Molecular Signature Database (http://software.
broadinstitute.org/gsea/index.jsp). The data demonstrate a
dose-dependent suppression of inflammatory gene expression
by heme, which is more pronounced in Hmox1 knockout cells at
lower heme concentrations than in wild-type macrophages. RT-
qPCR analysis of LPS-induced IL6 and Il12b mRNA expression
confirmed a left-shifted dose-response curve for the heme-
suppressive effect in Hmox1 knockout cells (red line)
compared to wild-type cells (black line) (Figure 6E).
Collectively, these results suggested that heme levels increasing
above physiological concentrations during hemolysis determined
A B
FIGURE 5 | Heme suppresses inflammation independently of iron levels (A) Heatmap displaying color-coded mRNA relative expression of proinflammatory and
anti-oxidative genes in BMDMs treated with the noniron porphyrin SnMP (top) or MnPP (bottom) for 4 h before stimulation with LPS (10 ng/mL) for an additional 4 h.
The data represent the mean expression values from three independent experiments (yellow=low expression, red=high expression). (B) Plasma ALT and AST
concentrations in C57BL/6J mice treated with or without SnMP-albumin (70 mmol/kg, i.p.) and after 4 h with anti-CD40 antibody for 30 h (20 mg/kg) (n = 3). From
these data, we could conclude that metalloporphyrins linked to albumin could replicate the inflammatory suppression of heme-albumin in vitro and in vivo.
****p < 0.0001, ***p < 0.001 for all panels.
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the anti-inflammatory macrophage response observed in
our experiments.
DISCUSSION
We found that acute PHZ-induced hemolysis leads to an increase in
intracellular heme in macrophages, which profoundly suppressed
macrophage-driven inflammatory liver disease induced by an
agonistic anti-CD40 antibody. This effect of hemolysis was
mimicked by the administration of heme-albumin complexes that
were specifically endocytosed by macrophages in the liver.
We designed our in vivo studies to mimic the two principal
pathways macrophages share to internalize hemoglobin and heme:
Erythrophagocytosis and endocytosis of hemoprotein-complexes






FIGURE 6 | Heme suppresses inflammation independently of its metabolites. (A) Western blot of HMOX1 in BMDMs from Hmox1fl/f UBC Cre-ERT2 (knockout) and
Hmox1fl/fl (wild-type) mice after exposure to heme-albumin concentrations ranging from 0 to 200 µM for 4 h and LPS treatment for an additional 4 h. Beta-actin was
used as a loading control. No HMOX1 expression is visible in the knockout macrophages. (B) Oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) of heme-albumin (50 mM)- and albumin (control)-exposed Hmox1 knockout and wild-type BMDMs were measured using a Seahorse XFe24 extracellular flux
analyzer. Measurements (n = 3) were recorded according to the standard protocol at baseline, after addition of oligomycin (an inhibitor of ATP synthase), after
addition of carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) (an uncoupling agent, which allows to measure maximum mitochondrial oxygen
consumption), and after addition of combined actinomycin A and rotenone (which shuts down mitochondrial respiration). (C) Correlation plot of mean mRNA
expression changes in wild-type (Hmox1fl/fl) and Hmox1-knockout (Hmox1fl/fl UBC Cre-ERT2) BMDMs that were treated with LPS for 4 h (n = 4 experiments). All
genes that were significantly upregulated by LPS are shown in pink (= LPS response). All the genes that define the hallmark “inflammation” gene set in the Molecular
Signature Database are depicted with enlarged dots (black and pink). (D) Selective presentation of relative expression data for the transcripts defining the “LPS
response” and “inflammation” classes across macrophages treated with LPS with/without heme. Statistical analyses of the average expression data were performed
by ANOVA with Tukey’s post hoc test for multiple comparisons. The data demonstrate a dose-dependent attenuation of the expression of LPS-induced genes with
increasing heme-albumin concentrations, and this effect was more pronounced in the absence of Hmox1 expression. (E) Relative expression of LPS-induced Il6 and
Il12b mRNA in BMDMs from Hmox1fl/fl UBC Cre-ERT2 mice (knockout, red) and Hmox1fl/fl mice (wild-type, black) in response to increasing heme-albumin
concentrations. The cells were treated with heme-albumin for 4 h before LPS stimulation. An expression level of 1.0 indicates the mean cytokine mRNA expression in
LPS-treated cells in the absence of heme-albumin. The data show the mean ± SD of six biological replicates measured in parallel. n.s., not significant.
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disease with extravascular hemolysis driven by excessive
erythrophagocytosis of damaged RBCs in the liver (40). We
found large numbers of macrophages with internalized RBCs and
high intracellular heme levels in the livers of mice following
treatment with PHZ. To mimic intracellular heme-exposure in an
erythrophagocytosis independent model, we established that heme
could be preferentially enriched in mouse liver macrophages after
administration of heme-albumin complexes. We confirmed this
idea by using ZnPP as a fluorescent heme-analog and spectral flow
cytometry, which allowed us to capture ZnPP-specific fluorescence
spectra in different cell types of liver single-cell suspensions.
Another essential feature of heme-albumin complexes in these
experiments was the previous observation in cell-culture that
these complexes could deliver heme into BMDMs without
triggering pro-inflammatory reactions (21).
To dissect the role of heme on macrophage functions, we
selected a CD40-ligation triggered inflammation model with
necrotizing hepatitis and cytokine release syndrome. This
disease phenotype is strictly driven by macrophage activation
(33). Both erythrophagocytosis and heme-albumin complex
administration dramatically attenuated the disease pathology,
suggesting that the anti-inflammatory block in our experiments
occurred at the level of macrophage activation. This was
supported by the observation that PHZ and heme-albumin
specifically inhibited the anti-CD40-induced pro-inflammatory
transcriptional response of liver macrophages.
Experiments with Hmox1 knockout BMDMs and with
Hmox1 inhibitory heme-analogs (SnMP and MnPP)
confirmed that heme, and not one of its metabolites, directly
transmits the anti-inflammatory signal in macrophages. The
observation that the presence or absence of Hmox1 dramatically
shifted the dose-response curve by which heme suppressed LPS-
induced cytokine release in macrophages suggests that HMOX1
might be a key coordinator of inflammatory and RBC
disposal functions.
Collectively, our study supports recent reports of anti-
inflammatory and immunosuppressive effects of chronic and
acute hemolysis. Our group has shown that mice with
spherocytosis and chronic hemolysis were resistant to anti-
CD40-induced necro-inflammatory liver disease and
nonalcoholic steatohepatitis (NASH) (22). In addition,
Olonisakin et al. reported that acute hemolysis induced by the
transfusion of stressed erythrocytes impaired the innate immune
response to Klebsiella pneumoniae infection, aggravating sepsis,
and mortality of infected mice (23). Both studies defined an anti-
inflammatory and immunosuppressive heme-signaling pathway
that includes heme-activation of Nfe2l2/Nrf2 with significant
suppression of Stat1 and interferon-regulated genes.
The macrophage-suppressive effects of heme in our studies
were profound. It is likely that in addition to Nfe2l2/Nrf2, a
synergistic signaling network drives the hypo-inflammatory
phenotype in macrophages. Numerous models of infection,
sterile inflammation, and transplantation have documented the
suppressive function of HMOX1 in innate immunity and
inflammation (41, 42). When present in excess, heme, and
downstream HMOX1 products might coactively suppress
macrophage functions. Other studies demonstrated that heme
activates liver-X-receptor (LXR)-coordinated gene expression
forcing macrophage differentiation into a phenotype with an
anti-inflammatory phenotype and high heme iron-metabolism
capacity (43–45). As a central integrator of metabolic and anti-
inflammatory signaling, LXR activation might consolidate the
effectors of the heme-induced anti-inflammatory macrophage
phenotype (46). Heme and other porphyrins can also inhibit the
proteasome to directly interfere with the activation of pro-
inflammatory NF-kB (47).
RBC-metabolism, iron-recycling, and immune-regulatory
functions of macrophages have been characterized in detail,
and hypo- or hyperactive failure of either process causes a
broad spectrum of diseases such as immunodeficiency,
inflammatory liver disease, metabolic diseases, macrophage
activation syndromes, anemia, or iron overload (i.e.,
hemochromatosis) (48–51). However, reciprocal interactions
of these archetypical macrophage functions during disease
pathogenesis have attracted less attention. Hemolysis with
excessive erythrophagocytosis in the liver and inflammatory
conditions are both frequent and may co-occur in individuals
with a genetic or acquired hemolytic anemia, in patients with
sepsis, during blood transfusion, or extracorporeal circulation.
Uncovering how hemolysis modulates inflammatory disease
processes may help better to understand the heterogeneity of
outcomes in those conditions and broaden the spectrum of
novel avenues towards personalized disease management.
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